Of interest, recent studies have reported that CCR2 deficiency or blockade additionally prevents myxomatous valve disease in MFS mice (51, 52), suggesting that antiinflammatory intervention on CCR2 may have multiple benefits for not only TAAs but also other manifestations of MFS. The gene discussed is CCR2; the disease is Marfan syndrome.